-
Sep. 27, 2018
Shionogi to Present Data on Cefiderocol and Baloxavir Marboxil at IDWeek 2018
OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi & Co., Ltd. (hereafter “Shionogi”) announced today that 14 presentations will feature the company’s investigational compounds at IDWeek™ 2018, in San Francisco, October 3-7, 2018. Shionogi will present data on cefiderocol (S-649266), a late-stage investigational siderophore cephalosporin with a novel mechanism of…
-
Sep. 5, 2018
Baloxavir Marboxil Phase II and III Studies for the Treatment of Influenza Published in the New England Journal of Medicine
OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced the positive results from Phase II and III studies of baloxavir marboxil for the treatment of influenza in otherwise-healthy patients have been published in the New…
-
Sep. 4, 2018
Shionogi Announces Upcoming Presentations from Symproic® (naldemedine) Studies at PAINWeek® 2018 Annual Conference
OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi & Co., Ltd. (hereafter “Shionogi”) will present four scientific posters featuring pre-clinical and clinical findings of Symproic® (naldemedine) during the 12th Annual PAINWeek® Conference, taking place September 4-8, 2018 in Las Vegas. Symproic is an oral tablet which functions as a peripherally…
-
Aug. 30, 2018
Shionogi Announces U.S. Availability of Mulpleta® (Lusutrombopag) for the Treatment of Thrombocytopenia in Adults with Chronic Liver Disease Scheduled to Undergo a Procedure
OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi & Co., Ltd. (hereafter “Shionogi”) announced today that Mulpleta® (lusutrombopag), a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure, is now…
-
Aug. 1, 2018
Shionogi Announces FDA Approval of Mulpleta® (Lusutrombopag)
Decision Marks Latest Once-Daily, Oral Treatment of Thrombocytopenia in Adults with Chronic Liver Disease Scheduled to Undergo a Procedure
-
Jul. 9, 2018
Shionogi Regains Full Rights to Symproic® (naldemedine) in the US
OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)– Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) has announced that effective immediately, Shionogi has regained full rights to Symproic® (naldemedine) tablets 0.2 mg in the United States. As Purdue Pharma L.P. is taking significant steps to transform and diversify…
-
Jun. 5, 2018
Shionogi Announces Upcoming Presentations at American Society for Microbiology Microbe Meeting
OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)– Shionogi & Co., Ltd. (hereafter “Shionogi”) announced today that eight scientific posters will feature the company’s investigational compounds at the American Society for Microbiology (ASM) Microbe meeting in Atlanta, June 7-11, 2018. Shionogi will present data on cefiderocol (S-649266), a late stage investigational siderophore cephalosporin with a novel…
-
Apr. 18, 2018
Shionogi to Present New Data at 2018 European Congress of Clinical Microbiology and Infectious Diseases
OSAKA, Japan–(BUSINESS WIRE)– Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced that the company will give 13 presentations on investigational agents at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in Madrid, Spain, April 21-24, 2018. Shionogi will present at this congress data on three investigational compounds including cefiderocol (S-649266), an investigational…
-
Feb. 26, 2018
Shionogi Announces FDA New Drug Application (NDA) and EMA Marketing Authorization Application (MAA) Acceptances for Lusutrombopag (S-888711)
In the United States, Lusutrombopag Granted Priority Review by the FDA
-
Nov. 21, 2017
Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill – a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
LONDON–(BUSINESS WIRE)– ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Juluca®, indicated as a complete regimen for the maintenance treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less…
